Search clinical trials for: DBPR108

Total 12 results

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Hepatic Impairment

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment

Renal Impairment

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Mass Balance and Biotransformation Study of [14C]DBPR108 in Human

Healthy Male Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM

Type 2 Diabetes Mellitus

China
National Health Research Institutes, Taiwan

Completed

A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects

Diabetes Mellitus, Type 2

Taiwan
National Health Research Institutes, Taiwan

Completed

A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects

Diabetes Mellitus, Type 2

Taiwan
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China

3

Subscribe